Latest news with #FUJIFILMVisualSonics
Business Wire
24-07-2025
- Health
- Business Wire
FUJIFILM Sonosite Redefines Superficial Imaging with the New UHF46-20 Transducer, the World's First 46MHz Ultra High Frequency Transducer for Point-of-Care Ultrasound
BOTHELL, Wash.--(BUSINESS WIRE)-- FUJIFILM Sonosite, Inc., the world leader in point-of-care ultrasound (POCUS) solutions, today announced a revolutionary advancement in point-of-care ultrasound imaging with the introduction of their UHF46-20 Transducer. This groundbreaking transducer is the first and only 46MHz Ultra-High Frequency (UHF) transducer available today in the point-of-care ultrasound market 1, setting a new standard for superficial image clarity and detail. With a minimum scan depth of 4mm, the UHF46-20 Transducer will enable clinicians to clearly visualize the first one to two centimeters beneath the skin and identify structures smaller than 1mm, such as superficial nerves and vessels, with high-quality resolution. Built upon the advanced Ultra High Frequency technology from FUJIFILM VisualSonics, and available exclusively on the FUJIFILM Sonosite LX POCUS system, this innovative technology provides the best superficial imaging 2,3,4 available on any point-of-care ultrasound system 1. 'At FUJIFILM Sonosite, we are driven by a commitment to help solve real-world challenges clinicians and providers face. The UHF46-20 transducer, when paired with the Sonosite LX system, enables the largest frequency range of any point-of-care ultrasound system on the market today - addressing a longstanding challenge that current clinical ultrasound systems have been unable to overcome,' said Richard Fabian, president and chief executive officer of FUJIFILM Sonosite, Inc. 'We're proud to bring to market the UHF46-20 Transducer as the first and only 46MHz UHF transducer in POCUS to provide clinicians with an unparalleled tool that may help them enhance diagnostic confidence and procedural accuracy.' The combination of the new transducer and the Sonosite LX offers clinicians a versatile solution for a wide spectrum of imaging needs, spanning from deep abdominal scans to ultra-high resolution superficial assessments. The UHF46-20 Transducer holds promise for improving outcomes across a range of sensitive applications including Neonatal Intensive Care Unit (NICU) and Rheumatology. In the NICU, its superior resolution may help clinicians see superficial submillimeter anatomy that conventional ultrasound may not capture. 6,11 The use of UHF ultrasound may aid clinicians in improving procedural quality by allowing for better visualization of tiny anatomy that may help to improve first attempt success rates. 4,8,9,10 In Rheumatology, UHF's advanced superficial imaging may aid in the visualization of subclinical synovitis, erosions, crystal deposits, and inflammation, all of which are beneficial in the early diagnosis and intervention of chronic conditions. 2,3,7 To learn more about the UHF46-20 Transducer, visit the product page at About FUJIFILM FUJIFILM Sonosite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by a global distribution network in over 100 countries. Sonosite's portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, please visit FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen. For more information, please visit: References Internal Fujifilm research as of April 2025. Albano, D., Aringhieri, G., Messina, C., De Flaviis, L., & Sconfienza, L. M. (2020). High-Frequency and Ultra-High Frequency Ultrasound: Musculoskeletal Imaging up to 70 MHz. Seminars in musculoskeletal radiology, 24 (2), 125–134. Russo, A.; Reginelli, A.; Lacasella, G.V.; Grassi, E.; Karaboue, M.A.A.; Quarto, T.; Busetto, G.M.; Aliprandi, A.; Grassi, R.; Berritto, D. Clinical Application of Ultra-HighFrequency Ultrasound. J. Pers. Med. 2022, 12, 1733. 10.3390/jpm12101733 Ait Ichou, J., Gauvin, S., & Faingold, R. (2021). Ultra-high-frequency ultrasound of superficial and musculoskeletal structures in the pediatric population. Pediatric radiology, 51 (9), 1748–1757. Hayashi, A., Giacalone, G., Yamamoto, T., Belva, F., Visconti, G., Hayashi, N., Handa, M., Yoshimatsu, H., & Salgarello, M. (2019). Ultra High-frequency Ultrasonographic Imaging with 70 MHz Scanner for Visualization of the Lymphatic Vessels. Plastic and reconstructive surgery. Global open, 7 (1), e2086. Latham, G. J., Veneracion, M. L., Joffe, D. C., Bosenberg, A. T., Flack, S. H., & Low, D. K. (2013). High-frequency micro-ultrasound for vascular access in young children--a feasibility study by the High-frequency UltraSound in Kids studY (HUSKY) group. Paediatric anaesthesia, 23 (6), 529–535. Viviano, S. L., Chandler, L. K., & Keith, J. D. (2018). Ultrahigh Frequency Ultrasound Imaging of the Hand: A New Diagnostic Tool for Hand Surgery. Hand (New York, N.Y.), 13(6), 720–725. Jacobsen RB, Hebelka H, Gatzinsky V, Elfvin A, Dangardt F. Ultra-high-frequency ultrasound (48–70 MHz) is a promising tool for improved gastrointestinal diagnostics in infants. Acta Paediatr. 2024; 113: 2304–2311. Brusciano, V., & Lecce, M. (2024). Advantages of the use of ultrasound in newborn vascular access: a systematic review. Journal of ultrasound, 27 (2), 203–207. Currie M, Vashisht R, Elkin D, et al. Ultrasound Intravascular Access. [Updated 2024 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Salvia, G.; Zerbinati, N.; Manzo Margiotta, F.; Michelucci, A.; Granieri, G.; Fidanzi, C.; Morganti, R.; Romanelli, M.; Dini, V. Ultra-High-Frequency Ultrasound as an Innovative Imaging Evaluation of Hyaluronic Acid Filler in Nasolabial Folds. Diagnostics 2023, 13, 2761. diagnostics13172761 Hawez, T., Evertsson, M., Erlöv, T. et al. The use of ultra-high frequency ultrasound in identifying aganglionosis in Hirschsprung's disease. Sci Rep 15, 15124 (2025).
Business Wire
26-06-2025
- Business
- Business Wire
FUJIFILM VisualSonics Launches the Vevo F2 LAZR-X20 Photoacoustic Imaging Platform for Preclinical Ultrasound
TORONTO--(BUSINESS WIRE)-- FUJIFILM VisualSonics Inc., a world leader in ultra-high frequency ultrasound and photoacoustic imaging systems, today announced the availability of the multi-modal Vevo F2 LAZR-X20 Photoacoustic Imaging Platform. The system features high-powered, intelligent laser technology for advanced tissue characterization with high anatomical accuracy for preclinical animal models. 'For more than two decades, FUJIFILM VisualSonics has been delivering ultra-high frequency ultrasound and photoacoustic imaging solutions to the scientific research community,' said Greg Nesbitt, vice president, global high frequency, FUJIFILM VisualSonics Inc. 'As a leader in the space, we saw an opportunity to expand the scope of questions that can be answered using photoacoustics. The Vevo LAZR-X20 underscores our commitment to constantly innovating and bringing more applications and capabilities to a broader set of research domains.' The advanced laser technology in the Vevo F2 LAZR-X20 provides enhanced imaging depth and high-resolution in real time, allowing researchers to visualize and measure various tissue types and contrast agents. Leveraging a unique wavelength range of 660-1320 nm, the system unlocks advanced tissue characterization capabilities that were beyond reach with our previous-generation technologies. Tissue chromophores like lipids and collagen, which exhibit unique absorption profiles within this range, can be detected non-invasively. This enables researchers to visualize tumor microenvironments and opens the potential for quantifying therapeutic efficiency. This paves the way for possible deeper insights and more impactful discoveries. 'This cutting-edge product represents a significant advancement in our portfolio, seamlessly integrating photoacoustics with ultrasound imaging into a single platform,' said Andrew Needles, director, product innovation, FUJIFILM VisualSonics Inc. 'The new system provides excellent image quality and an expanded spectral range, providing researchers with comprehensive data for their imaging studies. We believe this breakthrough technology will not only enhance current research capabilities but also has the potential to unlock new applications, particularly in the fields of oncology and neurobiology.' Learn more about the multi-modal Vevo F2 LAZR-X20 here. About Fujifilm FUJIFILM VisualSonics, Inc., is a global leader in real time, in vivo, ultra-high frequency ultrasound and photoacoustic imaging systems. With headquarters in Toronto, Canada and offices around the world, FUJIFILM VisualSonics is represented globally across an integrated sales network. FUJIFILM VisualSonics is recognized worldwide for providing cutting edge imaging technologies for the advancement of preclinical research, particularly in cardiovascular, oncology, neurobiology and developmental biology areas. With the expansion of the product portfolio to include a new preclinical product, FUJIFILM VisualSonics now broadens their range of imaging technologies across the preclinical market. FUJIFILM VisualSonics is a subsidiary of FUJIFILM Sonosite, Inc. and a part of FUJIFILM Holdings Corporation. For more information, please go to: FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here.
